Insider Selling: CEL-SCI Co. (NYSEAMERICAN:CVM) SVP Sells $56,240.00 in Stock

CEL-SCI Co. (NYSEAMERICAN:CVM) SVP John Cipriano sold 8,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $7.03, for a total transaction of $56,240.00. Following the transaction, the senior vice president now directly owns 91,108 shares of the company’s stock, valued at $640,489.24. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Shares of CVM traded up $0.09 during mid-day trading on Friday, hitting $7.59. 452,994 shares of the company’s stock were exchanged, compared to its average volume of 703,977. CEL-SCI Co. has a 52 week low of $2.37 and a 52 week high of $8.99.

CEL-SCI (NYSEAMERICAN:CVM) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.27). The firm had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.10 million.

Several institutional investors and hedge funds have recently modified their holdings of CVM. Jane Street Group LLC bought a new position in CEL-SCI during the second quarter worth $234,000. Morgan Stanley raised its stake in CEL-SCI by 12.0% in the second quarter. Morgan Stanley now owns 27,255 shares of the company’s stock valued at $228,000 after purchasing an additional 2,916 shares in the last quarter. Vanguard Group Inc. raised its stake in CEL-SCI by 35.2% in the second quarter. Vanguard Group Inc. now owns 1,332,334 shares of the company’s stock valued at $11,165,000 after purchasing an additional 346,999 shares in the last quarter. BlackRock Inc. raised its stake in CEL-SCI by 235.4% in the second quarter. BlackRock Inc. now owns 1,813,654 shares of the company’s stock valued at $15,199,000 after purchasing an additional 1,272,955 shares in the last quarter. Finally, Captrust Financial Advisors acquired a new position in CEL-SCI in the second quarter valued at about $25,000.

About CEL-SCI

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of primary head and neck cancer. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer.

See Also: Trading on Margin

Receive News & Ratings for CEL-SCI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI and related companies with MarketBeat.com's FREE daily email newsletter.